Pediatric exclusivity was sold as a safeguard.
A six-month extensionadded to the patent term of certain drugswas intended to reward companies for investing in childrens clinical studies and to ensure that pediatric patients arent left behind as product…

💥 Generic drug battles arent just courtroom dramastheyre business strategy with a filing deadline.
Bausch Health Companies (BHC) recently re-centered that reality in its ongoing dispute with Sun Pharmaceutical Industries (Sun Pharma) over patent p…

Drug pricing isnt a math problemits a patent war. And the latest Exelixis v. Intas fight shows whats really at stake.
If youve ever wondered why a generic takes years to reach pharmacy shelves (or why certain oncology drugs stay expensive longer than…

Exelixis vs. Handa: What the latest patent fight signals for drug pricingand deal timing
For anyone watching the intersection of Big Pharma, generics, and patent litigation, the latest update from Exelixis, Inc. v. Handa Pharmaceuticals, Inc. is more t…

🚨 Patent law rarely makes headlinesuntil it does. Todays takeaway from Takeda Pharmaceuticals U.S.A., Inc. v. Sun Pharmaceutical Industries, Ltd. is a reminder that in pharma, generic entry is never just a business decision. Its a legal and evidenti…

Vertex v. Squires: Why the Next Patent Fight in Rare Disease Matters Beyond the Courtroom
Rare disease patients dont have the luxury of waiting for timelines measured in years. Yet the mechanisms that decide whether therapies can stay on the marketor b…

Are you looking for Adefovir dipivoxil (brand Hepsera) and want info about a discount card (copay savings / patient savings… https://www.Drugchatter.com/chat/59984/adefovir-dipivoxil-discount-card/

Brand litigation isnt random. Its statistical.
Most teams treat PTAB outcomes like a black boxsomething you watch during the IPR process and only understand after the decision drops. But the smartest strategists are doing something different: theyre us…